The first-in-class BTK inhibitor approved by the Food and Drug Administration (FDA) in the US was ibrutinib for the treatment of chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma.11 The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.